Company Profile

ImmunoGen, Inc. is a commercial-stage biotechnology company. The Company is focused on developing and commercializing of antibody- drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its ELAHERE (Mirvetuximab Soravtansine) is a first-in-class ADC targeting folate receptor alpha (FRa), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Its Pivekimab sunirine (PVEK), is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. The Company is advancing PVEK in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).

Employees

277

Sector

Biotechnology & Medical Research

More about the company

24-02-20	AbbVie CEO to Retire; COO Robert Michael Named Successor	MT
24-02-13	BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase	AN
24-02-13	Biopharma Credit Secures $51 Million Loan Repayment from US Biotech ImmunoGen	MT
24-02-12	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P Global BMI Index	CI
24-02-12	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P TMI Index	CI
24-02-12	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P Biotechnology Select Industry Index	CI
24-02-12	Top Stories at Midday: Bezos Sells Nearly 12 Million Amazon Shares; Diamondback's $26 Billion Endeavor Energy Deal; Citigroup's Risk Management Procedures Rebuked; AbbVie Buys ImmunoGen	MT
24-02-12	AbbVie Completes $10.1 Billion Acquisition of ImmunoGen, Lowers Q1 Adjusted EPS Guidance	MT
24-02-12	AbbVie: acquisition of ImmunoGen finalized
24-02-12	AbbVie Acquires ImmunoGen for $31.26 per Share	MT
24-02-12	Immunogen, Inc. Announces Board Changes	CI
24-02-11	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index	CI
24-02-11	AbbVie Inc. completed the acquisition of ImmunoGen, Inc. from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc., State Street Corporation, The Vanguard Group, Inc. and others.	CI

23-12-04	Piper Sandler Downgrades ImmunoGen to Neutral From Overweight, Raises Price Target to $31 From $24	MT
23-12-01	Barclays Downgrades ImmunoGen to Equalweight From Overweight, Raises Price Target to $31 From $27	MT
23-12-01	Deutsche Bank Downgrades ImmunoGen to Hold From Buy, Adjusts Price Target to $31 From $25	MT
23-12-01	BMO Capital Downgrades ImmunoGen to Market Perform From Outperform, Price Target is $31	MT
23-12-01	Guggenheim Downgrades ImmunoGen to Neutral From Buy, Adjusts Price Target to $31 From $25	MT

24-02-12	AbbVie Completes Acquisition of ImmunoGen	PR
24-02-01	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
24-01-04	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
24-01-03	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
23-12-10	ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH	BU

24-02-12	Diamondback Energy : Abbvie, Diamondback Energy, Gilead...les valeurs à suivre aujourd'hui à Wall Street
24-02-12	Abbvie : abaisse ses perspectives après le rachat d'Immunogen
24-02-12	AbbVie : acquisition d'ImmunoGen finalisée
24-02-02	Omzetdaling Abbvie valt mee
24-01-22	HBM bleibt nach neun Monaten in den roten Zahlen

Manager	Title	Age	Since
Stacy Coen PRN	Corporate Officer/Principal	55	2020-06-02
Theresa Wingrove CTO	Chief Tech/Sci/R&D Officer	68	2011-01-23

ImmunoGen, Inc. Stock

Stocks

IMGN

US45253H1014

Biotechnology & Medical Research

Latest news: ImmunoGen, Inc.

Analysts' recommendations: ImmunoGen, Inc.

Press Releases: ImmunoGen, Inc.

News in other languages: ImmunoGen, Inc.

Managers and Directors: ImmunoGen, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/12/24	Richard Wallace	Issuer sale	Director	354,013	0.1267%
2/12/24	Daniel Char	Issuer sale	General Counsel	423,825	0.1517%
2/12/24	Mark Enyedy	Issuer sale	CHIEF EXECUTIVE OFFICER; Director	5,071,495	1.8154%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMMUNOGEN, INC.	-.--%	+6.73%	-	-	8.36B
WUXI APPTEC CO., LTD.	+0.34%	-3.03%	+37.45%	+61.06%	64.14B
ARGENX SE	+0.98%	+2.26%	+12.91%	+82.98%	55.53B
LONZA GROUP AG	+1.75%	+2.76%	+12.38%	+103.69%	53.03B
IQVIA HOLDINGS INC.	-1.43%	-0.57%	+26.10%	+52.86%	45.99B
BEONE MEDICINES AG	-0.48%	-3.86%	+17.27%	+117.99%	42.45B
REVOLUTION MEDICINES, INC.	+0.82%	-2.06%	+227.09%	+922.41%	40.45B
CELLTRION, INC.	-0.26%	-4.20%	+10.86%	+45.18%	32.25B
GENMAB A/S	-2.07%	+44.58%	+102.84%	+88.74%	34.47B
WUXI BIOLOGICS (CAYMAN) INC.	-2.72%	-8.79%	+22.58%	-5.63%	24.23B
Average	-0.31%	+3.82%	+52.16%	+163.25%	43.62B
Weighted average by Cap.	-0.07%	+3.13%	+49.26%	+160.88%